These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 14574034

  • 1. A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillation.
    Naccarelli GV, Wolbrette DL, Bhatta L, Khan M, Hynes J, Samii S, Luck J.
    J Interv Card Electrophysiol; 2003 Oct; 9(2):215-22. PubMed ID: 14574034
    [Abstract] [Full Text] [Related]

  • 2. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J.
    Am J Cardiol; 2003 Mar 20; 91(6A):15D-26D. PubMed ID: 12670638
    [Abstract] [Full Text] [Related]

  • 3. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
    Singh BN, Mody FV, Lopez B, Sarma JS.
    Am J Cardiol; 1999 Nov 04; 84(9A):161R-173R. PubMed ID: 10568677
    [Abstract] [Full Text] [Related]

  • 4. Oral antiarrhythmic drugs in converting recent onset atrial fibrillation.
    Deneer VH, Borgh MB, Kingma JH, Lie-A-Huen L, Brouwers JR.
    Pharm World Sci; 2004 Apr 04; 26(2):66-78. PubMed ID: 15085940
    [Abstract] [Full Text] [Related]

  • 5. Atrial fibrillation: choosing an antiarrhythmic drug.
    Rudo T, Kowey P.
    Curr Cardiol Rep; 2006 Sep 04; 8(5):370-6. PubMed ID: 16956453
    [Abstract] [Full Text] [Related]

  • 6. Arrhythmias in the intensive care patient.
    Trappe HJ, Brandts B, Weismueller P.
    Curr Opin Crit Care; 2003 Oct 04; 9(5):345-55. PubMed ID: 14508146
    [Abstract] [Full Text] [Related]

  • 7. Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation.
    Naccarelli GV, Hynes J, Wolbrette DL, Bhatta L, Khan M, Luck J.
    Curr Cardiol Rep; 2002 Sep 04; 4(5):418-25. PubMed ID: 12169239
    [Abstract] [Full Text] [Related]

  • 8. [Therapy of atrial fibrillation with class III anti-arrhythmia agents].
    Follath F, Candinas R, Frielingsdorf J.
    Herz; 1993 Feb 04; 18(1):20-6. PubMed ID: 8454249
    [Abstract] [Full Text] [Related]

  • 9. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ, Markham A.
    Drugs; 1999 Dec 04; 58(6):1043-59. PubMed ID: 10651390
    [Abstract] [Full Text] [Related]

  • 10. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence.
    Slavik RS, Tisdale JE, Borzak S.
    Prog Cardiovasc Dis; 2001 Dec 04; 44(2):121-52. PubMed ID: 11568824
    [Abstract] [Full Text] [Related]

  • 11. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A, Husser D, Cannom DS.
    Am J Cardiovasc Drugs; 2005 Dec 04; 5(6):371-8. PubMed ID: 16259525
    [Abstract] [Full Text] [Related]

  • 12. A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm.
    Tsikouris JP, Cox CD.
    Pharmacotherapy; 2001 Dec 04; 21(12):1514-29. PubMed ID: 11765303
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological management of atrial fibrillation: an update.
    Hohnloser SH, Li YG, Bender B, Grönefeld G.
    J Cardiovasc Pharmacol Ther; 2000 Jan 04; 5(1):11-6. PubMed ID: 10687669
    [Abstract] [Full Text] [Related]

  • 14. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia.
    Luedtke SA, Kuhn RJ, McCaffrey FM.
    Ann Pharmacother; 1997 Nov 04; 31(11):1347-59. PubMed ID: 9391691
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Intravenous and Oral Sotalol in Pharmacologic Conversion of Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Milan DJ, Saul JP, Somberg JC, Molnar J.
    Cardiology; 2017 Nov 04; 136(1):52-60. PubMed ID: 27554842
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials.
    Miller MR, McNamara RL, Segal JB, Kim N, Robinson KA, Goodman SN, Powe NR, Bass EB.
    J Fam Pract; 2000 Nov 04; 49(11):1033-46. PubMed ID: 11093570
    [Abstract] [Full Text] [Related]

  • 17. Antiarrhythmic drugs for the maintenance of sinus rhythm: risks and benefits.
    Camm J.
    Int J Cardiol; 2012 Mar 22; 155(3):362-71. PubMed ID: 21708411
    [Abstract] [Full Text] [Related]

  • 18. Rate-dependent electrophysiologic effects of the class III antiarrhythmic drugs nifekalant, amiodarone, and ibutilide on the atrium in patients with persistent atrial fibrillation.
    Sonoda K, Watanabe I, Ohkubo K, Okumura Y, Kofune M, Sasaki N, Kogawa R, Mano H, Nakai T, Hirayama A.
    Int Heart J; 2013 Mar 22; 54(5):279-84. PubMed ID: 24097216
    [Abstract] [Full Text] [Related]

  • 19. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm.
    Martínez-Marcos FJ, García-Garmendia JL, Ortega-Carpio A, Fernández-Gómez JM, Santos JM, Camacho C.
    Am J Cardiol; 2000 Nov 01; 86(9):950-3. PubMed ID: 11053705
    [Abstract] [Full Text] [Related]

  • 20. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials.
    Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, Mahé I, Bergmann JF.
    Arch Intern Med; 2006 Apr 10; 166(7):719-28. PubMed ID: 16606807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.